• Publications
  • Influence
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
TLDR
Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer.
American Cancer Society Guidelines for the Early Detection of Cancer
TLDR
Recommendations for the “cancer‐related check‐up,” in which clinical encounters provide case‐finding and health counseling opportunities, and an update of the most recent data pertaining to participation rates in cancer screening by age, gender, and ethnicity from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System and National Health Interview Survey.
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
TLDR
Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
TLDR
Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer.
Ovarian cancer statistics, 2018
TLDR
Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection.
American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical neoplasia and cancer, based on recommendations from a formal review and recent
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
TLDR
Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxfene in preventing noninvasive disease, with far less toxicity.
American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001—Testing for Early Lung
TLDR
The authors review the “cancer‐related check‐up,” clinical encounters that provide case‐finding and health counseling opportunities, and the ACS is issuing an updated narrative related to testing for early lung cancer detection for clinicians and individuals at high risk of lung cancer in light of emerging data on new imaging technologies.
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
TLDR
Full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure, and the use of fixed-dose chemotherapy is rarely justified.
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
TLDR
A systematic review of randomized controlled trials and meta-analyses published from June 2007 through June 2012 found six chemoprevention agents were identified and tamoxifen should be discussed as an option to reduce the risk of estrogen receptor -positive BC.
...
1
2
3
4
5
...